retapamulin

(redirected from Altabax)

retapamulin

(re-ta-pam-yoo-lin) ,

Altabax

(trade name)

Classification

Therapeutic: anti infectives
Pharmacologic: pleuromutilins
Pregnancy Category: B

Indications

Topical treatment of impetigo caused by methicillin-susceptibleStaphylococcus aureus or Streptococcus pyogenes.

Action

Interferes with bacterial protein synthesis at the level of the 50S ribosome.

Therapeutic effects

Bacteriostatic action against susceptible organisms.

Pharmacokinetics

Absorption: Minimal systemic absorption.
Distribution: Unknown.
Metabolism and Excretion: Small amounts absorbed are extensively metabolized.
Half-life: Unknown.

Time/action profile

ROUTEONSETPEAKDURATION
TopicalUnknownUnknown12 hr

Contraindications/Precautions

Contraindicated in: No contraindications.
Use Cautiously in: Obstetric: Use only in pregnancy when maternal benefit outweighs fetal risk; safe use during lactation not established; Pediatric: Safe use in children <9 mos not established.

Adverse Reactions/Side Effects

Dermatologic

  • application site irritation

Interactions

Drug-Drug interaction

Strong CYP3A4 inhibitors, including ketoconazole may ↑ levels; concomitant use not recommended in children <24 mo.

Route/Dosage

Topical (Adults and Children ≥9 mos) Apply thin layer to affected area (up to 100 cm2 in adults or 2% total body area in children) twice daily for 5 days.

Availability

Ointment: 10 mg/g in 5, 10 and 15 g tubes

Nursing implications

Nursing assessment

  • Assess lesions before and daily during therapy.
  • Monitor for application site irritation (redness, itching, burning, swelling, blistering, oozing). Discontinue, wipe off ointment and use alternative therapy if irritation occurs.

Potential Nursing Diagnoses

Risk for infection (Indications)
Risk for impaired skin integrity (Adverse Reactions)

Implementation

  • Topical: Apply a thin layer to affected area twice daily for 5 days. May be covered with sterile bandage or gauze if desired; may protect from access by infants and young children or accidental transfer to eyes or other areas. Wash hands after application if hands are not area of treatment. Avoid oral, intranasal, ophthalmic, or intravaginal use.

Patient/Family Teaching

  • Instruct patient or parent on correct application technique. Advise patient to apply medication exactly as directed for full course of therapy, even though symptoms have improved.
  • Teach patient and family appropriate hygienic measures to prevent spread of impetigo.
  • Instruct parents to notify school nurse for screening and prevention of transmission.
  • Advise patient to notify health care professional if application site irritation occurs or if there is no improvement within 3–4 days.

Evaluation/Desired Outcomes

  • Healing of skin lesions.
References in periodicals archive ?
Altabax is from the first new class of topical antibiotics approved in nearly 2 decades.
Comment: Efficacy was based in part on a clinical trial in which 139 children and adults with impetigo applied Altabax twice daily for 5 days while 71 others applied placebo ointment.
FDA ROUNDUP: GlaxoSmithKline PLC won approval to market its new anti-bacterial treatment Altabax to treat the skin infection impetigo, caused by strains of Staphylococcus aureus or Streptococcus pyogenes--the two most common types of bacteria in this kind of infection.
GlaxoSmithKline Receives FDA Approval for Altabax II-52
Food and Drug Administration has issued an approvable letter for its topical antibacterial, Altabax (retapamulin ointment), 1%, for the treatment of secondarily-infected traumatic lesions (SITL).
In the letter to GSK, the FDA requested additional information to complete its assessment of Altabax as a treatment for SITL; no safety concerns were noted.
We are excited to combine GSK's prescription dermatology products, such as Bactroban, Cutivate and Altabax, with Stiefel's portfolio, including brands such as Duac, Olux E and Soriatane.
GSK's key dermatology brands include: Bactroban, Cutivate and recently launched Altabax.
Most recently he worked on the GlaxoSmithKline, Altabax, and Trexima accounts for IMC2, an interactive marketing agency in Dallas, Texas.
Food and Drug Administration (FDA) has approved its antibacterial Altabax for the topical treatment of impetigo due to susceptible strains of Staphylococcus aureus or Streptococcus pyogenes, the two most common types of bacteria in this kind of infection.
Altabax represents the first new class of prescription topical antibacterials to be approved by the FDA in nearly two decades.